Skip to main
PRVA
PRVA logo

PRVA Stock Forecast & Price Target

PRVA Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 67%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Privia Health Group Inc has successfully executed Care Partners deals, achieving a 20% year-over-year growth in MSSP beneficiaries, a notable increase in savings rates by 150 basis points, and the implementation of over 100 providers since their $25 million acquisition of CMG in February 2023. The company has demonstrated a strong ability to enter new markets while recognizing the importance of organic growth among providers in existing markets to meet long-term targets. As Privia scales through partnerships with large health systems and medical groups, it remains focused on expanding its networks by engaging individual physicians, which underscores its commitment to optimizing physician practices and enhancing patient care.

Bears say

Privia Health Group Inc. faces a challenging outlook as its operating partners are anticipating a notable decline in Medicaid enrollment, projected at 8%-10% on a same-store basis by year-end. This decline is attributed to re-determination activities following the conclusion of the public health emergency, which is expected to negatively impact revenue and operational stability. As Medicaid plays a vital role in the healthcare landscape, the expected decrease in membership could hinder Privia Health's growth prospects and overall financial performance.

PRVA has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 67% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Privia Health Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Privia Health Group (PRVA) Forecast

Analysts have given PRVA a Buy based on their latest research and market trends.

According to 12 analysts, PRVA has a Buy consensus rating as of Oct 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Privia Health Group (PRVA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.